|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-11-24
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Acute myocardial infarction (MI) remains a leading cause of death despite advances in pharmacologic and percutaneous therapies. Animal models of ischemia/reperfusion have demonstrated that single-dose erythropoietin may reduce infarct size, decrease apoptosis, and increase neovascularization, possibly through mobilization of endothelial progenitor cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
pubmed-author:FerrucciLuigiL,
pubmed-author:HarringtonRobert ARA,
pubmed-author:KilaruRakhiR,
pubmed-author:KimRaymond JRJ,
pubmed-author:LakattaEdward GEG,
pubmed-author:LongoDan LDL,
pubmed-author:MelloniChiaraC,
pubmed-author:MeltonLauraL,
pubmed-author:NajjarSamer SSS,
pubmed-author:PatelManesh RMR,
pubmed-author:PovsicThomas JTJ,
pubmed-author:RaoSunil VSV,
pubmed-author:TalanMarkM
|
|
pubmed:copyrightInfo |
Copyright © 2010 Mosby, Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
160
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
795-803.e2
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21095264-Aged,
pubmed-meshheading:21095264-Dose-Response Relationship, Drug,
pubmed-meshheading:21095264-Double-Blind Method,
pubmed-meshheading:21095264-Electrocardiography,
pubmed-meshheading:21095264-Erythropoietin,
pubmed-meshheading:21095264-Follow-Up Studies,
pubmed-meshheading:21095264-Heart Ventricles,
pubmed-meshheading:21095264-Hematinics,
pubmed-meshheading:21095264-Humans,
pubmed-meshheading:21095264-Injections, Intravenous,
pubmed-meshheading:21095264-Magnetic Resonance Imaging, Cine,
pubmed-meshheading:21095264-Myocardial Infarction,
pubmed-meshheading:21095264-Recombinant Proteins,
pubmed-meshheading:21095264-Recovery of Function,
pubmed-meshheading:21095264-Treatment Outcome,
pubmed-meshheading:21095264-United States,
pubmed-meshheading:21095264-Ventricular Function, Left,
pubmed-meshheading:21095264-Ventricular Remodeling
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial.
|
|
pubmed:affiliation |
Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. chiara.melloni@duke.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase II,
Research Support, N.I.H., Intramural
|
